PDS Biotechnology
PDSB
46 hedge funds and large institutions have $82.4M invested in PDS Biotechnology in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.
476% more capital invested
Capital invested by funds: $14.3M → $82.4M (+$68.1M)
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
44% more funds holding
Funds holding: 32 → 46 (+14)
7.85% more ownership
Funds ownership: 14.13% → 21.98% (+7.8%)
30% less call options, than puts
Call options by funds: $2.75M | Put options by funds: $3.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$11.7M |
| 2 |
BlackRock
New York
|
+$2.8M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$2.72M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$2.18M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.75M |
| 2 |
Renaissance Technologies
New York
|
-$1.66M |
| 3 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
-$207K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$201K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$195K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LNC
51
Lincoln National Corp
Radnor,
Pennsylvania
| – | -$76K | -16,647 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$48K | -10,602 | Closed |
|
53
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$48K | -10,500 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$18K | -4,000 | Closed |
|
|
TCWM
55
Total Clarity Wealth Management
St. Charles,
Illinois
| – | -$7K | -1,500 | Closed |
|
56
Group One Trading
Chicago,
Illinois
| – | -$195 | -25 | Closed |
|
57
Fidelity Investments
Boston,
Massachusetts
| – | +$8 | +1 | New |
|
|
IA
58
IFP Advisors
Tampa,
Florida
| – | +$86 | +11 | New |
|
PDSB Hedge Fund Activity: Q2 2021 in Review
46 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2021, worth a combined $82.4M — up 476% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PDSB positions and 12 closed out — a net gain of 14 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $11.7M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.75M sold.
- 46 institutional investors held PDS Biotechnology (PDSB) as of Q2 2021, up from 32 in Q1 2021.
- Funds reported $82.4M of PDS Biotechnology stock for Q2 2021, up 476% quarter-over-quarter.
- 26 funds opened new PDS Biotechnology positions in Q2 2021 and 12 closed out, a net change of +14 holders.
- The largest PDS Biotechnology buyer in Q2 2021 was AIGH Capital Management, an estimated $11.7M added.
- The largest PDS Biotechnology seller in Q2 2021 was Ikarian Capital, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2021.